The first and only rosuvastatin formulation that eliminates the need to crush tablets and is designed for patients who cannot or will not swallow solid forms of medication.¹
Ezallor SprinkleTM (rosuvastatin) is indicated as adjunctive therapy to diet for the treatment of adults with hypertriglyceridemia, primary dysbetalipoproteinemia, and adjunctive therapy to other lipid-lowering treatments (or alone if unavailable) for those with homozygous familial hypercholesterolemia.¹
Approximately 4 in 10 American adults cannot or will not
swallow solid forms of medication.²
For your patients who encounter issues swallowing solid medications, choose Ezallor SprinkleTM and the flexibility of its 3 administration options, which have bioavailability equivalent to Crestor® (rosuvastatin calcium).1,3 Ezallor SprinkleTM requires no crushing for patients who cannot or will not swallow solid medication forms. Simply open, sprinkle, and serve.1
Choose the flexibility of 3 administration options.
Open and sprinkle over soft food
Administer via nasogastric tube
No Need to Crush Pills—Just Open, Sprinkle, and Serve.
Avoid medication errors, deliver the full dose
Because Ezallor SprinkleTM eliminates the need to crush pills, patients can avoid the potential errors and associated risks that can accompany the pill crushing process.1,4,5 For your patients who cannot control their cholesterol levels with diet and exercise alone, Ezallor SprinkleTM delivers rosuvastatin in a unique formulation designed to ensure those who cannot or will not swallow solid forms of medication can still get the full dose, as prescribed.¹
When your patients on statins cannot or will not swallow solid medication forms, switch them to Ezallor SprinkleTM to eliminate the need to crush tablets.¹
References: 1. Ezallor SprinkleTM [prescribing information]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc., 2020. 2. Center for Drug Evaluation and Research, US Food and Drug Administration. Size, Shape, and Other Physical Attributes of Generic Tablets and Capsules: Guidance for Industry.www.fda.gov/media/87344/download. Published June 2015. Accessed January 6, 2020. 3. Data on file. Sun Pharmaceutical Industries Inc., Princeton, NJ. 4. Thong MY, Manrique YJ, Steadman KJ. Drug loss while crushing tablets: comparison of 24 tablet crushing devices. PLoS ONE. 2018;13(3):e0193683. doi.org/10.1371/journal.pone.0193683. 5. Joint Commission International. Joint Commission International Accreditation Standards for Long Term Care. 1st ed. Oak Brook, IL: Joint Commission International; 2012.